A Novel Balanced Dual Vasopressin V1a/V2 Receptor Antagonist for Treatment of Congestive Heart Failure: Results From a First-in-Man Study

被引：0
|
作者：
Pimenta, Eduardo
Jensen, Markus
Jung, David
Lobmeyer, Maximilian
Schmitt, Walter
Schaumann, Frank
Boxnick, Stefanie
Truebel, Hubert
机构：
来源：
CIRCULATION | 2017年 / 136卷
关键词：
Heart failure; Vasopressins; Abdominal aortic aneurysm;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
15196
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Is there a cardiovascular rationale for the use of combined vasopressin V1a/V2 receptor antagonists?
    Goldsmith, Steven R.
    AMERICAN JOURNAL OF MEDICINE, 2006, 119 : S93 - S96
  • [32] Pharmacological characterization of YMO87, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist
    Tahara, A
    Saito, M
    Sugimoto, T
    Tomura, Y
    Wada, K
    Kusayama, T
    Tsukada, J
    Ishii, N
    Yatsu, T
    Uchida, W
    Tanaka, A
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 357 (01) : 63 - 69
  • [33] TREATMENT WITH THE V1A/V2-VASOPRESSIN RECEPTOR ANTAGONIST CONIVAPTAN INCREASES CARDIAC OUTPUT DURING EXERCISE IN PATIENTS WITH ADVANCED HEART FAILURE
    Balling, Louise
    Thomsen, Jakob H.
    Wolsk, Emil
    Hassager, Christian
    Boesgaard, Soeren
    Goldsmith, Steven
    Gustafsson, Finn
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 1319 - 1319
  • [34] In vivo and in vitro characterisation of a nonpeptide vasopressin V1A and V2 receptor antagonist (YM087) in the rat
    Risvanis, J
    Naitoh, M
    Johnston, CI
    Burrell, LM
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 381 (01) : 23 - 30
  • [35] Coupling between V1a and V2 vasopressin receptor transduction pathways.
    Klingler, C
    Barrault, MB
    Ancellin, N
    Morel, A
    Corman, B
    Friedlander, G
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1996, 7 (09): : A0103 - A0103
  • [36] Three Cases of Tolvaptan, that is Vasopressin V2 Receptor Antagonisut, is Effective of Congestive Heart Failure
    Fujiwara, Syouhei
    Yuba, Masao
    Tateishi, Jun
    Masuyama, Tohru
    JOURNAL OF CARDIAC FAILURE, 2011, 17 (09) : S166 - S166
  • [37] Urinary water clearance after infusion of conivaptan, a combined vasopressin V1A and V2 receptor antagonist, in patients with NYHA class III/IV heart failure
    Painchaud, C
    Bichet, D
    Udelson, JE
    Ghazzi, MM
    Selaru, P
    Chartier, K
    EUROPEAN HEART JOURNAL, 2001, 22 : 394 - 394
  • [38] Hemodynamic effects of short-term infusion of a vasopressin V1A/V2 receptor antagonist conivaptan in patients with chronic heart failure during submaximal exercise
    Balling, Louise
    Wolsk, Emil
    Hassager, Christian
    Boesgaard, Soren
    Goldsmith, Steven R.
    Gustafsson, Finn
    AMERICAN HEART JOURNAL, 2018, 203 : 101 - 104
  • [39] Urinary water clearance after infusion of conivaptan, a combined vasopressin V1a and V2 receptor antagonist, in patients with NYHA class III/IV heart failure
    Painchaud, CA
    Ghazzi, MM
    Selaru, P
    Bichet, DG
    Chartier, KK
    Udelson, JE
    CIRCULATION, 2000, 102 (18) : 535 - 535
  • [40] Effect of long-term treatment with selective vasopressin V1 and V2 receptor antagonist on the development of heart failure in rats
    Nishikimi, T
    Kawano, Y
    Saito, Y
    Matsuoka, H
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1996, 27 (02) : 275 - 282
12345